Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Brain Injury Association of America honors Centre for Neuro Skills’ Dr. Mark Ashley with Sheldon Berrol MD Clinical Service Award

Centre for Neuro Skills

The Brain Injury Association of America (BIAA) recognized Dr. Mark J. Ashley, CEO and founder of Centre for Neuro Skills (CNS), at the American Congress of Rehabilitation Medicine’s (ACRM) Centennial Conference as the recipient of the 2023 Sheldon Berrol MD Clinical Service Award on October 31, 2023. The award honors the person who has made “outstanding contributions to improving the quality of care, professional training, and/or education in the field of brain injury” in their career. “As someone who knew and worked with Dr. Sheldon Berrol, “Shelly,” witnessing his unwavering commitment to improving patient care and independence first-hand, I’m truly honored to receive this award,” says Dr. Mark Ashley. Dr. Ashley founded CNS in 1980 after his brother, Steve, experienced a life-changing event, leaving him cognitively intact, but dependent on a ventilator. Conventional medicine and available rehabilitative therapies gave his brother little hope for significant recovery or regaining an independent life, but Dr. Ashley believed that Steve could overcome the odds and that rehabilitation was possible through an intense therapy program. His brother became one of CNS’ first patients, and his recovery became the model for the brain injury rehabilitation provider’s philosophy. Steve’s recovery galvanized a belief that people with brain injuries should have a place to heal, and Dr. Ashley and his family could provide this essential service. Dr. Ashley’s dedication to understanding brain injury through personal experience, treating patients and research has helped countless patients over his 40 years of developing clinical therapies. He established the Clinical Research and Education Foundation, a nonprofit research organization that advances public and clinical understanding of brain injury causes and treatment in 2011. He has served on numerous committees and boards for organizations focused on brain injury treatment, research and outcomes. A published author on brain injury rehabilitation, Dr. Ashley has not only written books but also had his work and research published in peer-reviewed journals and research publications. Dr. Ashley received a Master of Science degree in Speech Pathology and holds a Doctor of Science degree from Southern Illinois University in Carbondale, Ill. He received a Doctor of Science degree from State University of New York at Geneseo. He is a licensed Speech Language Pathologist in California and Texas and is both a Certified Case Manager and Certified Brain Injury Specialist Trainer. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-971-3991 cns@landispr.com Company Website https://www.neuroskills.com/

November 01, 2023 08:01 AM Pacific Daylight Time

Image

RHIZOME AND PAUL G. ALLEN FAMILY FOUNDATION ANNOUNCE PARTNERSHIP TO ADVANCE CIVIC EDUCATION IN WASHINGTON SCHOOLS

Paul G. Allen Family Foundation

Seattle, WA — Today, Rhizome and the Paul G. Allen Family Foundation announced a $620,000 initiative aimed at creating a new Civic Service Fellowship program in Washington high schools. This three-year initiative will establish over 100 teams of Fellows in hyperlocal Chapters across the state of Washington. Rhizome’s Civic Service Fellowship prioritizes rural communities, under-resourced areas, and communities of color. The Civic Service Fellowship will empower high school students to lead year-round initiatives designed to boost civic engagement within their schools and communities. This will include organizing community events, educating younger students about democracy, and assisting their eligible peers with voter registration or pre-registration. Students have the opportunity to mend divisions, combat disengagement, and address the mental health crisis by creating civic communities. By inviting students to gain leadership experience and build healthy habits based on who they want to become, Rhizome inspires responsibility and produces pathways for lifelong leadership and public engagement. Civic participation can be an important factor for young people’s social and mental well-being. Recent research from Gallup has found that less than half of Gen Z members feel as though they are “thriving” and only 44% feel prepared for their future. While 76% of young people across the country believe their age group has the power to enact change, only 40% of all youth—and only 34% of youth of color—report feeling well-qualified to participate in politics. In an era marked by diminishing public trust and worsening mental health outcomes among young people, this initiative will equip students with the tools to engage their communities in building a healthier world for all. “After 90 of us came together as Co-Founders of Rhizome just two years ago, we are thrilled to announce this multi-year partnership with the Paul G. Allen Family Foundation, addressing the need for sustainable systems that empower emerging leaders to shape change,” said Jacob Merkle, Rhizome’s CEO. “In an era of unmet challenges to our civic and mental health, this collaboration allows Rhizome to scale our grassroots system, deepen our impact, and build collective power for young people. We’re grateful for the Foundation's recognition that young people are the future. We hope this early commitment will spur philanthropy to provide more scale-enabling, no-strings-attached funding for young people to create the safer, happier, and healthier world they deserve.” “Witnessing the growth of Rhizome from day one has been one of the most fulfilling experiences in my life. Not simply the growth of the organization, but the tangible difference that has been made in the confidence of countless students. As an organizer in Washington, my proudest moment is seeing the transformation in students as they gain their voice to fearlessly advocate for their own beliefs,” said Hiba Siddiqui, a Rhizome Regional Organizer who works in Eastern Washington. “Having the support of partners like the Paul G. Allen Family Foundation reaffirms our mission and gives us the resources to expand our reach. I am excited to see the indelible impact that will be made as Rhizome brings our community of trust, friendship, and belonging to other areas in Washington.” “Civic education is necessary now more than ever. Our civic landscape has shifted and testifies to the urgency to actively involve youth in bettering their communities and solving societal issues. As a committed civic educator for over two decades, I cannot emphasize enough how important it is to have partners in this mission,” said Jen Reidel, a Social Studies and English teacher at Bellingham High School. “I can provide classroom experiences, but I need like - minded civic organizations like Rhizome to help students find their civic identities and mission outside the classroom.” According to Ms. Reidel, Rhizome removes the responsibility of supporting a student club outside of class from the teacher and places it on the students and their Rhizome mentor. It honors student agency and diversity by equipping students to promote civic engagement within their school and identify issues they would like to address at a local level and authentically work toward their solution. Funds from the partnership will directly support student-led efforts by paying a dedicated team of Rhizome’s student organizers in Washington, who will work to implement the Civic Service Fellowship in local schools in their communities. By funding this important work, Rhizome and the Paul G. Allen Family Foundation are investing deeply in the next generation of lifelong civic leaders. About Rhizome Founded in 2021, Rhizome is a national network of student leaders organizing to empower young people to build stronger communities. Rhizome was co-founded by 90 young people to help students become more civically active while training the next generation of organizers and emerging leaders. Learn more at www.werhize.org. About the Paul G. Allen Family Foundation Founded in 1988 by philanthropists Jody Allen and the late Paul G. Allen, co-founder of Microsoft, the foundation invests in communities across the Pacific Northwest to enhance the human experience of arts & culture, center under-served populations, and mobilize young people to make impact. In addition, the foundation supports a global portfolio of nonprofit partners working across science and technology solutions to protect wildlife, preserve ocean health, and create lasting change. The foundation also funds the Paul G. Allen Frontiers Group, which works to advance cutting-edge research in all areas of bioscience. Contact Details Rhizome Maya Rodriguez, Communications Director +1 415-488-7692 mayar@werhize.org Company Website https://www.werhize.org

November 01, 2023 08:00 AM Pacific Daylight Time

Image

Living with Acromegaly: Spreading Awareness and Highlighting Treatment Options on Acromegaly Awareness Day

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/y696riLIIKs For more information, visit MYCAPSSA.COM Acromegaly is a rare condition that affects about 25,000 people living in the U.S. It is caused by a benign tumor in the pituitary gland which is located just beneath the brain. This benign tumor makes too much growth hormone, and this can cause various issues such as fatigue, headaches, and increased growth of hands and feet and pretty much every part of the body. If not treated, acromegaly can cause high blood sugar as in Diabetes and high blood pressure, and sometimes cause serious damage to the heart which can be life-threatening. The good news is that there are some very good treatments available to help control the problem. A nationwide media tour was conducted on October 23rd to discuss the drug MYCAPSSA as well as to hear about the experiences of someone living with acromegaly. The media tour featured Dr. Anthony P. Heaney, Professor at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Becky Bierman, a person living with acromegaly. Mycapssa, is a twice-daily oral medication that reduces the production of growth hormone and is designed for people who have previously been on an injectable version of octreotide therapy for the long-term maintenance of acromegaly. During the media tour Dr. Heaney and Becky discussed: · What acromegaly is and how many people it affects. · What it is like living with acromegaly. · Treatment options available for someone living with this disease. People diagnosed with acromegaly considering a new treatment option should talk to their doctors first. For more information, you can visit www.Mycapssa.com Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 01, 2023 09:57 AM Eastern Daylight Time

Video

HKBU studies show over half of COVID-19 patients have post-disease syndrome

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 1 November 2023 - The School of Chinese Medicine at Hong Kong Baptist University (HKBU) found that 55% of the patients who sought medical treatment from the "HKBU Chinese Medicine Telemedicine Centre Against COVID-19" during the fifth wave of the COVID-19 pandemic continued to experience at least one long COVID symptom for six months to a year after diagnosed with an infection. The most common symptoms are fatigue, brain fog and cough. Professor Bian Zhaoxiang, Director of the Clinical Division at HKBU’s School of Chinese Medicine (middle), together with his research team members Mr Cheung Chun-hoi, Associate Director of the Clinical Division (2nd left); Dr Zhang Jialing, Postdoctoral Fellow of the Centre for Chinese Herbal Medicine Drug Development (1st left); Mr Luo Jingyuan and Wong Hoi-ki, PhD students (2nd and 1st right) of SCM at HKBU, analyse patient statistics to deepen the medical community’s understanding of the symptoms during the early and middle stages of COVID-19 infection as well as the post-COVID syndrome. The study also revealed that patients who took Chinese medicine after COVID-19 infection took a shorter time to test negative in rapid tests, and experienced significant symptom relief compared to patients who did not take Chinese medicine. The research findings have been published in a number of papers in international academic journals including the Journal of Medical Virology and The American Journal of Chinese Medicine. HKBU established the "HKBU Chinese Medicine Telemedicine Centre Against COVID-19" in 2021 during the fifth wave of the COVID-19 pandemic in Hong Kong to provide free telemedical services for COVID-19 patients. Making reference to the treatment protocols and clinical experiences in Mainland China, the expert team of HKBU's School of Chinese Medicine formulated the "Chinese Medicine Clinical Guidelines for COVID-19 in Hong Kong" as the University's clinical diagnosis and treatment standards for COVID-19. The Telemedicine Centre follows the guidelines to provide diagnosis, treatment, and prevention services to COVID-19 patients, close contacts, and caregivers. Coughing is the most common early symptom of infection The HKBU research team led by Professor Bian Zhaoxiang, Director of the Clinical Division at the School of Chinese Medicine, conducted a retrospective study using patient statistics collected by the Telemedicine Centre during the fifth wave of the pandemic. The team analysed the symptoms in the first four weeks of about 13,000 patients who were infected with COVID-19 from mid-March to early May in 2022 and underwent home isolation. The results showed that 93% of patients experienced at least one symptom. The most common symptoms during the first week of infection were cough (91%), sputum (75%), dry throat (50%) and sore throat (44%). 17% of patients still had these symptoms four weeks after infection. Although the symptoms gradually subsided over time, the prevalence of fatigue increased. Chinese medicine accelerates viral clearance Among this batch of patients, the research team selected 311 patients who had taken Chinese medicine for five days within 10 days after diagnosis, and another 311 patients who had not taken any Chine medicine during the same period to evaluate the efficacy of Chinese medicine. The results showed that patients who took Chinese medicine within 10 days after COVID-19 infection needed an average of seven days to test negative in rapid tests, and experienced an average of four symptoms, which were significantly milder compared to patients who didn't take Chinese medicine. The average time to test negative for patients who did not take Chinese medicine was eight days, and they experienced an average of 11 symptoms. The results show that Chinese medicine is an effective treatment for COVID-19 infection. Over half of the patients experience long COVID after six months The research team conducted a follow-up telephone survey from November 2022 to January 2023 with 6,242 COVID-19 patients who sought medical consultation at the Telemedicine Centre between December 2021 and May 2022 to understand their symptoms and risk factors after six months to a year of infection. The study found that 55% of patients still experienced at least one long-term symptom, i.e. "long COVID" or "post-COVID syndrome". The most common symptoms were fatigue (36%), brain fog (34%) and cough (31%). Furthermore, females, middle-aged persons, obese people, those with comorbidities such as ophthalmology or otorhinolaryngology diseases, digestive system diseases, respiratory diseases, hyperlipidemia and cardiovascular diseases, and patients with more initial symptoms were more likely to develop long COVID. However, there was no significant correlation between taking three or more doses of vaccine and the occurrence of long COVID. Professor Bian said: "HKBU established the Telemedicine Centre during the COVID-19 outbreak to provide free treatments for COVID-19 patients. We analysed the Centre's data to deepen the medical community's understanding of the symptoms during the early and middle stages of COVID-19 infection as well as the post-COVID syndrome. It allows the public to understand the effectiveness of Chinese medicine in treating COVID-19. The study also shows that the tele-services of Chinese medicine can be an important component of Hong Kong's healthcare and disease prevention system." To address the issues of long COVID, Professor Bian's team has initiated a series of clinical and basic research, including a survey of COVID-19 patients with diabetes and a clinical trial conducted in collaboration with other partners to investigate the efficacy, safety and action mechanism of senlingcao oral liquid in treating long COVID fatigue. These projects aim to further explore the impact of COVID-19 and its treatment options. Contact Details Christina Wu christinawu@hkbu.edu.hk

November 01, 2023 09:00 AM Eastern Daylight Time

Image

DPH Biologicals, University of Illinois Team Up to Improve Crop Residue Management

DPH Biologicals

• Trials focus on benefits of biologicals for post-harvest stubble control • First-year results unveiled October 30 at international agronomy sciences meeting DPH Biologicals and the University of Illinois Urbana-Champaign (UIUC) announced today a research collaboration validating the impact biologicals make to accelerate decomposition of crop residue, thereby unlocking the adoption of more sustainable and profitable farming practices for United States high-yield, broadacre growers. Starting in spring of 2023, the UIUC Crop Physiology Lab run by Fred Below, Ph.D. and Connor Sible, Ph.D., began researching the impact of microbial solutions in crop residue management including the use of TerraTrove® Residuce®, technology developed by DPH Bio. Residuce is a biodigester, a biological specifically formulated to accelerate the process of plant tissue degradation. “Supporting Dr. Below’s lab is an opportunity to ground-truth the benefits of biodigesters, understand how technologies like Residuce can enable more sustainable and profitable cropping practices and to develop best practice use recommendations supporting our retail and channel partners with high-value, science-verified cropping solutions,” said Alex Cochran, Ph.D., DPH Bio’s Chief Technology Officer. A subset of biofertilizers, biodigester sales are exploding as part of the expanding global biofertility market, projected to reach $3.75 billion USD in sales by 2030, a CAGR of 12.80%, underpinned by market demand for more sustainably-grown food with farmers’ need to offset increasing costs and shrinking profit margins. Residuce, available in a liquid and dry formulation, is currently used on 1.5 million North American acres, a 50% growth rate in the past year. Already, early UIUC trial results indicate improved yields when biodigesters were used with cover crop plantings. Cover crops are typically associated with lower yields, a correlation that has discouraged grower adoption despite the well-known soil health benefits of cover cropping. Using Residuce on an unmanaged cereal rye cover crop partially eliminated the nearly nine-bushel yield penalty average experienced when a cover crop is planted between no-till corn and soybean rotations, according to research presented Monday by UIUC graduate student Darby Danzl at the 2023 ASA, CSSA, SSSA International Annual Meeting, held jointly by the American Society of Agronomy, the Crop Science Society of America and the Soil Science Society of America. The yield penalty was nearly fully eliminated when a fertilizer source was combined with Residuce. Research Focuses on Value-Creation of Biodigesters for Corn, Soybean and Wheat Production With UIUC already a research leader in residue management strategies in broadacre cropping systems, the ongoing field trial collaborations with DPH Bio will focus on further defining the value biodigesters bring to unlocking the value of residue for sustainable agriculture. DPH Bio recently published “ Rethinking Crop Residue Management with Biodigesters,” an analysis of research into crop residue management, includes work already completed by the UIUC crop physiology lab as well as DPH Bio’s field trial results. The UIUC-DPH partnership will expand upon the research and benefits of biodigesters presented in the white paper. Large volumes of crop residue create problems, Sible said, with high-yielding cultivars and practices like no-till, double-cropping and cover cropping generating more residue than growers’ have ever experienced. Today’s average 180-bushel corn crop yields 3.9 tons per acre of corn stover and every additional bushel in yield contributes another 43.7 pounds of stover, according to UIUC research. Growers complain of delayed germination, poor plant stands, nutrients locked up in the decomposing process, increased disease and pest outbreaks from pathogens that overwinter in thick residue layers and yield penalties associated with residue accumulation. Yet, once broken down, residue is an untapped source of nutrients and better soil and crop health. Strategies for accelerating residue degradation are key, Below said. “Residue is nature’s biological. It’s so good for the soil and the plant, and there's a lot of nutrition there. But residue can be your best friend or your worst nightmare,” Below said. “The quicker you can degrade residue, the easier you can plant, the more uniform your crop is going to emerge and the more likely you’re going to get the benefits of that residue.” The next round of joint UIUC-DPH Bio trials will focus on: ● The benefits of biodigesters for cover crop management in no-till corn and soybean. ● Fall versus spring residue management with biodigesters to benefit continuous corn yield. ● Biodigesters value to residue management in a wheat-soybean double crop rotation. Studies conducted in 2023 will be available this winter. The second round of trial results will be available before the 2025 planting season. About DPH Biologicals DPH Biologicals aims to be the industry’s most trusted biologicals provider. We attract, develop and scale technologies improving broad market access and simplifying the grower experience with biologicals. With more than three decades invested into scientific research, field-testing, partner relationships and product development, we’ve built three proven product platforms – BellaTrove® for biocontrols; TerraTrove® for biofertility and biodigesters; and RegenAphex™, a regenerative, plant-based humus extract that serves as a foundation for our flagship biofertilizer SP-1 Classic and a platform for third-party technological development. For more information, visit www.dphbio.com. Contact Details AgTech PR for DPH Bio Georgie Smith georgie@agtechpr.com Company Website http://www.dphbio.com

November 01, 2023 08:30 AM Eastern Daylight Time

Image

CURE ALZHEIMER’S FUND RECEIVES $50,000 GRANT FROM GREATER TOLEDO COMMUNITY FOUNDATION

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund (CureAlz), a non-profit dedicated to funding the most promising research to end Alzheimer’s disease, received a $50,000 grant from the Robert A. Stranahan, Jr. Charitable Advised Fund of the Greater Toledo Community Foundation. This grant represents their largest gift to Cure Alzheimer’s Fund since the Robert A. Stranahan, Jr. Charitable Advised Fund made its first grant to the non-profit in 2016. Through eight years of consecutive giving, the fund has provided $235,000 to CureAlz scientists working to find a cure. “Year after year, we are more encouraged by the progress Cure Alzheimer’s Fund is making to understand Alzheimer’s disease,” said Keith Burwell, President of Greater Toledo Community Foundation. “Our continued philanthropic support provides necessary funding for research that accelerates the discoveries that will eventually tackle Alzheimer’s disease and find a cure.” “The Greater Toledo Community Foundation recognizes the physical, emotional and financial impact this disease has on so many families in its community and around the world and has been a wonderful partner to CureAlz in our mission to find a cure,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Alzheimer’s devastates not just individual patients but their family and community as well. Developing effective, accessible therapies requires deep understanding of the complex causes and pathologies of Alzheimer’s. The scientists CureAlz supports are pursuing vital high-risk, high-reward research to accelerate progress. We are deeply grateful to the Greater Toledo Community Foundation for sharing our goal to end the burden of Alzheimer’s.” It is estimated that more than 6.5 million Americans are currently living with Alzheimer’s disease, a number that is expected to increase rapidly as the Baby Boomer generation continues to age. It is projected that the share of adults 65 and older in the US population will rise to 22 percent by 2050. With age as the biggest risk factor, Alzheimer’s disease is poised to place an unmanageable financial burden on the US healthcare system, caregivers, and loved ones. With the philanthropic support of the Robert A. Stranahan, Jr. Charitable Advised Fund of the Greater Toledo Community Foundation and tens of thousands of other donors, CureAlz has been able to direct more than $180 million to Alzheimer’s disease research since its inception in 2004 and has delivered critical breakthroughs for the research community. About Greater Toledo Community Foundation Greater Toledo Community Foundation is a public charitable organization created by citizens of our community to enrich the quality of life for individuals and families in our area. In existence since 1973, the Foundation has more than 970 individual current funds with assets of approximately $406 million. The Foundation provides philanthropic services for individuals, families, businesses and corporations to meet their charitable giving needs. For more information on the Foundation, visit the organization’s website at www.toledocf.org or follow them on Facebook or LinkedIn. About Cure Alzheimer’s Fund Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100 percent of funds raised going to support research, Cure Alzheimer’s Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, please visit https://www.curealz.org/. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org

November 01, 2023 05:51 AM Eastern Daylight Time

News Release

Perimeter Medical Imaging AI initiates new clinical trial site in Seattle, WA

Perimeter Medical Imaging AI

Adrian Mendes, the CEO of Perimeter Medical Imaging, joined Steve Darling from Proactive with news that the company has initiated an additional clinical trial site at the University of Washington in the Fred Hutch Cancer Center. Perimeter's clinical trial is a multi-center, randomized, two-arm pivotal study that evaluates the investigational Perimeter B-Series Optical Coherence Tomography (OCT) technology. This technology is combined with Perimeter's proprietary ImgAssist AI software and is used during breast conservation surgeries. The core of this innovative approach is the use of ultra-high-resolution, real-time, advanced imaging tools to examine excised tissues at the cellular level, providing crucial insights to surgeons. Mendes emphasized the significance of this additional clinical trial site, as it plays a vital role in gathering valuable data generated during the study. This data will be instrumental in supporting the commercialization of Perimeter's B-Series technology. The company's ultimate goal is to transform cancer surgery by providing advanced technology that not only improves patient outcomes but also helps reduce healthcare costs. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 31, 2023 03:22 PM Eastern Daylight Time

Video

News Release

1606 Corp announces cutting-edge AI-driven CHATCBDW is live and in operation

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news the company has officially unveiled its cutting-edge AI chatbot, ChatCBDW, which represents a significant advancement in the world of CBD products and customer engagement. Lambrecht explained that ChatCBDW has undergone key designs and rigorous testing before being launched and is now live and operational. This innovative chatbot offers a wide range of user-centric features that go beyond the ordinary. One of its standout attributes is its capability to respond to user inquiries and provide comprehensive education on all aspects of CBD. However, ChatCBDW doesn't stop there. It takes personalization to the next level by offering tailored product recommendations to users and engaging in conversations that closely mimic human interaction. This level of innovation empowers customers to make well-informed choices, explore a diverse array of CBD products, and promises an unparalleled shopping experience within the CBD industry. The seamless integration of ChatCBDW with Microsoft Azure is a key component of its capabilities. Microsoft Azure is renowned for its scalability, unwavering reliability, and cutting-edge AI functionalities. This integration ensures that ChatCBDW can operate impeccably, even during periods of peak demand, delivering users a consistently responsive and seamless experience throughout their interaction with the chatbot. The company has also announced that Cool Blue Distribution is now a North American licensed reseller of ChatCBDW and is set to engage its network of over 800 CBD retailers immediately. The first direct-to-merchant marketing campaign is scheduled to begin by mid-November 2023, with the goal of generating notable revenue before January 1, 2024. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 31, 2023 03:16 PM Eastern Daylight Time

Video

PathAI Announces Research Presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions with end-to-end central pathology and histology services, today announced it will present research underscoring the efficacy of PathExplore’s human interpretable features (HIFs) through three poster presentations at the Society for Immunotherapy of Cancer’s 38 th Annual Meeting on November 1-5 in San Diego, CA. The posters showcase how PathExplore provides high-resolution characterization of the tumor microenvironment (TME) through a standardized panel of HIFs derived from H&E whole slide images across multiple cancer types. Additionally, Incendia Therapeutics will present two posters reporting results that were generated utilizing PathExplore. “Building upon past publications and presentations, we continue to see the utility for histological features of the tumor microenvironment to further our understanding of disease biology, patient prognosis, and therapeutic response, which ultimately may lead to the discovery and implementation of novel biomarkers to advance precision medicine,” explained Mike Montalto, Ph.D., Chief Scientific Officer, PathAI. All three posters demonstrate the correlation between specific HIFs and established molecular measurements of the TME (e.g., gene expression profiles of specific cell populations), as well as specific HIFs and complex molecular signatures (e.g., immune phenotypes) which could better aid in the identification of patients eligible for targeted therapies, or result in the identification of new histology-based biomarkers. Quantifying the effect of microsatellite instability and mismatch repair deficiency on the tumor microenvironment (Poster 73) In this research, PathAI investigated the potential to predict and compare microsatellite stability and mismatch repair subtypes in colorectal and endometrial cancers utilizing PathExplore HIFs. The findings suggest MSS/dMMR tumors may warrant consideration for immunotherapy due to their TME’s similarity to microsatellite instability-high (MSI-H) and tumor mutation burden-high (TMB-H) solid tumors and AI-powered analysis of H&E WSI presents a more accessible and scalable method than current dMMR testing options. This poster will be presented by Judy Chen and Shima Nofallah on Friday, November 3 rd. Poster hall hours are 9 a.m. to 7 p.m. PT. Quantification of tumor infiltrating lymphocytes (TILs) from pathology slides reflects molecular immune phenotypes (Poster 122) In this research, PathAI deployed its PathExplore products on H&E WSI across eight cancer indications to extract HIFs quantifying the TME, including features that represent TIL fractions, densities, and distributions. Analysis revealed statistically significant correlations between TIL-associated HIFs with gene expression of known lymphocyte markers, as well as immune signature scores such as lymphocyte infiltration. These results show the predictive power that TIL-associated HIFs have for identifying immune phenotypes, as well as a promising direction for the discovery of histology-based immune biomarkers. This poster will be presented by Judy Shen on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Deep learning models identify key tumor microenvironment features associated with genetic signatures of UV metagenesis and alkylating agent treatment in melanoma (Poster 110) In this research, PathAI used PathExplore HIFs to investigate the association between TME features and mutational signatures indicative of UV mutagenesis, as well as alkylating agents-induced mutations. The results suggest that quantifying a tumor’s tissue and cellular composition can reveal meaningful information regarding the underlying mutation-driven or treatment-induced changes in the TME, which may have implications for therapy selection. This poster will be presented by Shima Nofallah on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Incendia Therapeutics (formerly known as Parthenon Therapeutics) posters In addition to the posters above, Incendia Therapeutics will present two posters on Friday, November 3 rd reporting results that were generated utilizing PathExplore. One poster (Poster 1287) compares PathExplore HIFs to mIF features and concluded that "TME models are a robust tool to distinguish tissue and cell features from H&E slides, comparable to mlF image analysis, but requiring less effort, time, and expense." In the second (Poster 1497), Incendia Therapeutics leveraged HIFs quantifying lymphocyte densities across cancer epithelium, cancer stroma, and the epithelial-stromal interface (ESI) to characterize barriers to lymphocyte entry into the cancer epithelium across immune phenotypes. More information on these posters can be found at https://www.incendiatx.com Please visit the PathAI booth, 615, to learn more and meet the team, or email us at bd@pathai.com. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 31, 2023 10:00 AM Eastern Daylight Time

1 ... 53 54 55 56 57 ... 221